Yashwant Kumar

Yashwant Kumar

Auto-generated profile, based on publicly available information

Yashwant Kumar

Noncommunicable Diseases, Translational Health Science and Technology Institute, Faridabad, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2021 in Science Advances
Verified
Journal Article
Open access
ZRZAIGHAM ABBAS RIZVI
ZAIGHAM ABBAS RIZVI
RDRajdeep Dalal
Rajdeep Dalal
SSSrikanth Sadhu
Srikanth Sadhu
YKYashwant Kumar
Yashwant Kumar
SKShakti Kumar
Shakti Kumar
AAAmit Awasthi
Amit Awasthi
Salt triggers tumor immunity through microbiota-mediated NK cell activation.

22 September 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
APArchana Pant
Archana Pant
SBSatyabrata Bag
Satyabrata Bag
BSBipasa Saha
Bipasa Saha
JVJyoti Verma
Jyoti Verma
PKPawan Kumar
Pawan Kumar
BDBhabatosh Das
Bhabatosh Das
Significance: Genome fluidity is directly associated with the emergence and evolution of many bacterial pathogens. Horizontally acquired genetic elements, which harbor fitness traits, are open source for the bacterial evolution. The genome of Vibrio cholerae is equipped with multiple mobile genetic elements (MGEs), which are crucial for disease development and survival. The present study engineered the genome of a well characterized clinical V. cholerae strain N16961 and reported ( i ) stability of MGEs in cholera pathogen, ( ii ) interactions between the core genome and MGEs, and ( iii ) role of MGEs in the modulation of cellular proteome. The engineered strain could be a potential candidate for understanding evolution of cholera pathogen and development of new therapeutic interventions.

3 January 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SCSaurabh Chugh
Saurabh Chugh
PTPrabhakar Tiwari
Prabhakar Tiwari
CSCharu Suri
Charu Suri
SGSonu Kumar Gupta
Sonu Kumar Gupta
PSPadam Singh
Padam Singh
RSRamandeep Singh
Ramandeep Singh
Inorganic polyphosphate (polyP) is primarily synthesized by Polyphosphate Kinase-1 (PPK-1) and regulates numerous cellular processes, including energy metabolism, stress adaptation, drug tolerance, and microbial pathogenesis. Here, we report that polyP interacts with acyl CoA carboxylases, enzymes involved in lipid biosynthesis in Mycobacterium tuberculosis . We show that deletion of ppk-1 in M. tuberculosis results in transcriptional and metabolic reprogramming. In comparison to the parental strain, the Δ ppk-1 mutant strain had reduced levels of virulence-associated lipids such as PDIMs and TDM. We also observed that polyP deficiency in M. tuberculosis is associated with enhanced phagosome–lysosome fusion in infected macrophages and attenuated growth in mice. Host RNA-seq analysis revealed decreased levels of transcripts encoding for proteins involved in either type I interferon signaling or formation of foamy macrophages in the lungs of Δ ppk-1 mutant–infected mice relative to parental strain–infected animals. Using target-based screening and molecular docking, we have identified raloxifene hydrochloride as a broad-spectrum PPK-1 inhibitor. We show that raloxifene hydrochloride significantly enhanced the activity of isoniazid, bedaquiline, and pretomanid against M. tuberculosis in macrophages. Additionally, raloxifene inhibited the growth of M. tuberculosis in mice. This is an in-depth study that provides mechanistic insights into the regulation of mycobacterial pathogenesis by polyP deficiency.

25 February 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
ADAbhilasha Dwivedi
Abhilasha Dwivedi
AAAnjali Anjali
Anjali Anjali
HNHina Narzari
Hina Narzari
YKYashwant Kumar
Yashwant Kumar
HSHanuman Prasad Sharma
Hanuman Prasad Sharma
AGAnu Gupta
Anu Gupta
Background: Amnestic mild cognitive impairment (aMCI) represents a transitional stage between normal aging and Alzheimer disease (AD), where early intervention is critical for preserving cognition and delaying or preventing progression to dementia. Due to the limited availability of curative pharmacological treatments, there is growing interest in traditional and indigenous medicinal interventions, such as Bacopa monnieri (Linn.) or Brahmi, a widely used Ayurvedic nootropic herb. Bacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis. These pathways have been implicated in MCI due to AD pathophysiology. Hence, the efficacy of Bacopa in aMCI and the mediating metabolic changes need to be systematically evaluated through clinical trials. Objective: The aim of this study is to assess the effects of B. monnieri on cognitive function and plasma metabolites in individuals with aMCI (early or prodromal AD). Methods: This study will employ a double-blind, randomized, placebo-controlled trial design, with 76 participants (38 per group) of aMCI diagnosed using the clinical National Institute on Aging–Alzheimer’s Association 2011 criteria in a tertiary care setting in India. Participants will receive either B. monnieri (Linn.) (300 mg standardized plant extract) or a matched placebo daily for 12 weeks. Comprehensive cognitive assessments (0, 12, and 24 wk) and untargeted plasma metabolomic profiling (0 and 12 wk) will be conducted to evaluate both cognitive changes and alterations in plasma metabolites. MetaboAnalyst 6.0 (with integrated features like Kyoto Encyclopedia of Genes and Genomes and the Human Metabolome Database) will be used for a comprehensive statistical and functional analysis pertaining to the metabolomics. The primary outcome will be a change in the composite z score of memory between the 2 groups at 12 weeks. The secondary outcomes will include alterations in metabolites and pathways, and adverse events at 12 weeks, and cognitive performance at 12 and 24 weeks. Results: The study was funded in October 2023, and the first participant was enrolled in April 2024. As of November 2025, a total of 60 participants have been recruited, with a mean (SD) age of 62.2 (8.1) years. The cohort predominantly comprises men (53/60, 88.3%), individuals with at least a high school education (47/60, 78.3%), and participants at elevated risk for cognitive decline. Specifically, 39 of 60 participants (65%) have diabetes, 29 (48.3%) have hypertension, and 13 (21%) report a positive family history of dementia. Data collection will conclude in June 2026, after which data analysis will begin and be completed by September 2026, with primary findings targeted for publication in spring 2027. Conclusions: This protocol investigates the efficacy of B. monnieri (Linn.) in improving cognitive function and altering the blood metabolites in patients with aMCI. If effective, this intervention could provide an accessible and cost-effective approach to manage early AD in resource-limited settings.

3 August 2022 in Free Radical Research
Verified
Journal Article
Closed access
HAHobby Aggarwal
Hobby Aggarwal
PPPriya Pathak
Priya Pathak
SGSonu Kumar Gupta
Sonu Kumar Gupta
YKYashwant Kumar
Yashwant Kumar
KJKumaravelu Jagavelu
Kumaravelu Jagavelu
MDMadhu Dikshit
Madhu Dikshit
Involvement of NOX-dependent oxidative stress in the pathophysiology of metabolic disorders as well as in the maintenance of metabolic homeostasis has been demonstrated previously. In the present study, the metabolic profile in p47phox–/– and WT mice fed on a chow diet was evaluated to assess the role of metabolites in glucose intolerance and dyslipidemia under altered oxidative stress conditions. p47phox–/– mice displayed glucose intolerance, dyslipidemia, hyperglycemia, insulin resistance (IR), hyperinsulinemia, and altered energy homeostasis without any significant change in gluconeogenesis. The expression of genes involved in lipid synthesis and uptake was enhanced in the liver, adipose tissue, and intestine tissues. Similarly, the expression of genes associated with lipid efflux in the liver and intestine was also enhanced. Enhanced gut permeability, inflammation, and shortening of the gut was evident in p47phox–/– mice. Circulating levels of pyrimidines, phosphatidylglycerol lipids, and 3-methyl-2-oxindole were augmented, while level of purine was reduced in the serum. Moreover, the cecal metabolome was also altered, as was evident with the increase in indole-3-acetamide, N-acetyl galactosamine, glycocholate, and a decrease in hippurate, indoxyl sulfate, and indigestible sugars (raffinose and melezitose). Treatment of p47phox–/– mice with pioglitazone, marginally improved glucose intolerance, and dyslipidemia, with an increase in PUFAs (linoleate, docosahexaenoic acid, and arachidonic acid). Overall, the results obtained in p47phox–/– mice indicate an association of IR and dyslipidemia with altered serum and cecal metabolites (both host and bacterial-derived), implying a critical role of NOX-derived ROS in metabolic homeostasis. Graphical Abstract

14 November 2024 in Physiologia Plantarum
Verified
Journal Article
Closed access
DSDeepika Singh
Deepika Singh
HZHaohao Zhao
Haohao Zhao
SGSonu Kumar Gupta
Sonu Kumar Gupta
YKYashwant Kumar
Yashwant Kumar
Jeongim KimJeongim Kim
Jeongim Kim
PPPrashant Pawar
Prashant Pawar